Dr. Mezhebovsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 South St
Brookline, MA 02467Phone+1 617-469-0300Fax+1 617-783-0395
Education & Training
St Elizabeth's Medical CenterResidency, Psychiatry, 1994 - 1997
Perm State Medical Academy Class of 1977
Certifications & Licensure
MA State Medical License 1996 - 2026
Clinical Trials
- Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Start of enrollment: 2013 Nov 01
- Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD Start of enrollment: 2016 Jan 01
Publications & Presentations
PubMed
- Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target.Mark Mintz, Victor Badner, Lynn K Feldman, Pnina Mintz, Mana Saraghi
Psychopharmacology Bulletin. 2022-06-27 - 26 citationsDouble-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.Irina Mezhebovsky, Kairi Mägi, Fahua She, Catherine Datto, Hans Eriksson
International Journal of Geriatric Psychiatry. 2013-06-01 - 2 citationsExtended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A...Arifulla Khan, Sarah Atkinson, Irina Mezhebovsky, Fahua She, Todd Leathers
Psychopharmacology Bulletin. 2011-05-15
Press Mentions
Experimental Drug Offers Hope to Those Living with OCDAugust 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
